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ABSTRACT
Background and Objectives: In patients with neurocardiogenic syncope or presyncope, symptoms developed unpredictably 
and intermittently. The purpose of this study was to determine whether there was any significant difference in the recurrence rate 
of symptoms during the follow-up period between patients with many episodes of symptoms and those with fewer episodes of 
symptoms before diagnosis, as well as to assess the clinical significance of previous episodes of symptoms during treatment. 
Subjects and Methods: A total of 100 patients with neurocardiogenic syncope or presyncope were divided in two groups 
(high episode group, n=54; low episode group, n=46) according to the frequency of symptoms before the head-up tilt test. We 
retrospectively analyzed the recurrence of symptoms using telephone interviews and medical record reviews. Results: The 
clinical characteristics were not significantly different between the two groups. However, the recurrence rate was significantly 
lower in the high episode group than in the low episode group (5.6% vs. 19.6%, p=0.001). In the high episode group, patients 
treated with medication showed higher recurrence of symptoms than those without medication. In the lower episode group, a 
similar result was observed. Conclusion: The frequency of previous symptoms at the diagnosis of neurocardiogenic syncope 
or presyncope did not predict the occurrence of symptoms during the follow-up period. Therefore, to continue drug treatment 
based on the frequency of symptoms in patients with neurocardiogenic syncope or presyncope may not be the best option. 
(Korean Circ J 2011;41:434-439)
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Introduction
Neurocardiogenic syncope is the most common cause of syn-
cope, which occurs in response to various stimuli such as pro-
longed standing, fear, pain and others. These stimuli cause an 
exaggerated response of the autonomic nervous system. Neu-
rocardiogenic syncope usually develops after prolonged st-
anding and increased sympathetic activity. Under this condi-
tion, exaggerated myocardial contraction of left ventricle ac-
tivates myocardial mechanoreceptors and vagal afferent nerve 
fibers that lead to sympathetic inhibition and parasympathetic 
activation. Finally, peripheral vasodilation and bradycardia 
cause the occurrence of syncope.
1) However, the pathophysi-
ology of neurocardiogenic syncope is not simple and other fac-
tors are also involved.
2) 
A detailed history taking is the most important diagnostic 
step in evaluating patients with suspected neurocardiogenic 
syncope. Head-up tilt test (HUT) is widely used to confirm di-Seon Mee Lee, et al.   435
agnosis in patients with unexplained syncope.
3)4) The shorter 
time interval between the last episode and HUT was a predic-
tor of the positive response of HUT in patients with suspected 
neurocardiogenic syncope or presyncope.
5) However, there 
were only a few studies to evaluate the recurrence of symp-
toms during follow-up in patients with a positive HUT.
6)7)
Therefore, the purpose of this study was to determine whe-
ther there was any significant difference in the recurrence rate 
of symptoms during follow-up between patients with a high 
episode of symptoms and those with a low episode of symp-
toms before diagnosis, as well as to assess the clinical signifi-
cance of previous episodes of symptoms during treatment.
Subjects and Methods
Study population
One hundred and seventy-six consecutive patients with su-
spected neurocardiogenic syncope or presyncope, who sh-
owed a positive response of HUT, were recruited at Samsung 
Medical Center, Seoul, Korea, between January 2000 and 
December 2000. The medical records and HUT case report 
forms of these 176 consecutive patients were retrospectively re-
viewed. Of these, 100 patients who agreed to a telephone in-
terview to discuss the recurrence of symptoms following HUT 
were included in this study. However, 76 patients were excl-
uded from the study because they declined to give a teleph-
one interview. The selected 100 patients with neurocardio-
genic syncope or presyncope were divided into two groups bas-
ed on the frequency of symptoms before HUT. One group 
was defined as the high episode group (n=54), in which pa-
tients experienced five or more episodes of symptoms. The 
other group was defined as the low episode group (n=46), in 
which they experienced less than five episodes of symptoms. 
Head-up tilt test
All patients underwent HUT in a fasting state after ob-
taining informed consent and HUT consisted of two phases. 
The first phase of HUT was performed while patients were 
tilted to an angle of 70° for 30 minutes, or until symptoms ap-
peared. If the first phase produced a negative response, the 
second phase with isoproterenol provocation was performed 
while maintaining the same degrees of tilting as the first ph-
ase for 15 minutes. Isoproterenol was intravenously admin-
istered at an initial rate of 1 µg/min. The infusion rate was in-
creased by 1 µg/min every 3 minutes to a maximum of 5 µg/
min. Electrocardiography was continuously monitored. The 
blood pressure of each patient was non-invasively measured 
beat-to-beat using a Finapres (OhMeda Monitoring System, 
Englewood, CO, USA) during the HUT.
5) A positive response 
of HUT was defined when syncope or presyncope was re-
produced in association with hypotension, bradycardia, or 
both. Positive responses were classified into three types (va-
sodepressive, cardioinhibitory, mixed) according to the cri-
teria provided in the previous study, in which a vasodepres-
sive response was defined as significant systolic blood pres-
sure decrease <80 mmHg. A cardioinhibitory response was de-
fined as abrupt sinus arrest or heart rate decrease (sinus arrest 
>3 seconds or heart rate <45 beats/min in the first phase, heart 
rate <60 beats/min in the second phase). A mixed response 
was defined as significant decrease of systolic blood pressure 
and heart rate.
8)
Symptom recurrence during follow-up
We evaluated symptom recurrence by telephone interview 
as well as by reviewing patient medical records. We defined 
the recurrence of symptoms as syncope if the patient experi-
enced a syncopal episode during the follow-up period. We 
also defined the recurrence of symptoms as presyncope if the 
patients experienced severe prodromal symptoms such as diz-
ziness, weakness, and sweating which disappeared by sitting 
or acquiring the supine position during the follow-up period. 
Statistical analysis
Means were calculated for continuous variables and the 
frequency was measured for categorical variables. Compari-
sons were made by Student’s t-test for continuous variables, 
and the chi-square test was used for categorical variables. A 
p<0.05 was considered statistically significant. Data were 
analyzed with Statistical Package for the Social Sciences (SPSS), 
Version 11.0 (SPSS, Inc., Chicago, IL, USA). Multivariate re-
gression analysis was used to identify possible independent va-
riables associated with symptom recurrence during follow-up.
Results
Baseline clinical characteristics of total patients
The mean age was 37±15 years (n=100); 50% were male. 
The mean episode of syncope was 3.9±6.3. The mean episode 
of presyncope was 18.4±63.2. 16% were taking drugs to pre-
vent symptoms. 21% had underlying disease. 28% had a phy-
sical injury during syncopal episodes (Table 1). 
Comparison of clinical characteristics between high 
and low episode groups
The frequency of symptoms before HUT was very diverse 
in both groups (Fig. 1). There was no significant difference of 
clinical characteristics between high and low episode groups. 
However, syncope and presyncopal episodes were more fre-
quently noted in the high episode group (5.9±7.9 vs 1.5±1.3, 
33.3±83.5 vs. 1.0±1.3, p=0.003) (Table 1).
Comparison of parameters during head-up tilt test 
between high and low episode groups 
There was no significant difference observed in the pattern 436   Recurrence Rate in Neurocardiogenic Syncope
of positive response of HUT between high and low episode gr-
oups. Vasodepressive type was the most common and cardio-
inhibitory type was the least common in both groups. How-
ever, positive response of HUT was more frequently observ-
ed at the first phase of HUT in the high episode group (15% 
vs. 4%, p=0.001) (Table 2).
 
Symptom recurrence during follow-up
The mean duration of follow-up was 38.4±3.6 months. 
Twelve patients (12%) experienced symptoms during fol-
low-up. Three patients were found in the high episode group 
and all showed a vasodepressive response during HUT. Nine 
patients were found in the low episode group. Vasodepressive 
response was noted in four patients, mixed response in four 
patients, and cardioinhibitory response in one patient dur-
ing HUT. The recurrence of symptoms was significantly less 
in patients with high episodes of symptoms than in those 
with low episodes of symptoms (5.6% vs. 19.6%, p=0.001) 
Table 1. Comparison of clinical characteristics between patients with high episode of symptoms and low episode of symptoms
  Groups
Variables
High episode group (n=54) Low episode group (n=46) p Total 
Age (years) 38±16 40±15 NS 37±15
Male/Female 25/29 25/21 NS 50/50 
Syncope/Presyncope 5.9±7.9/33.3±83.5 1.5±1.3/1.0±1.3 0.003 3.9±6.3/18.4±63.2
Medication (%) 10 (18) 06 (13) NS 16 (16)
Underlying disease (%) 11 (20) 10 (21.7) NS 21 (21)
Physical injury (%) 16 (30) 12 (26) NS 28 (28)
Data: mean±SD. NS: not significant 
Table 2. Comparison of parameters during head-up tilt test between patients with high episode of symptoms and low episode of symptoms
           Groups
Variables
High episode group (n=54) Low episode group (n=46) p
Pattern of positive response (%)
Vasodepressive type 35 (67) 29 (63) NS
Cardioinhibitory type 5 (9) 4 (9) NS
Mixed type 13 (24) 13 (28) NS
Phase of positive response (%)
Passive (the first phase) 08 (15) 2 (4) 0.001
Isoproterenol provocation (the second phase) 46 (85) 44 (96) NS
NS : not significant
Fig. 1. Histograms of syncopal and presyncopal episodes in both groups.
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(Figs. 2 and 3). 
Comparison of recurrence of symptoms between 
patients with and without medication 
during follow-up
Of 54 patients with high episodes of symptoms, 10 patients 
were on medication to prevent symptom recurrence. Two of 
10 patients (20%) experienced symptom recurrence. Forty fo-
ur patients did not take any medication to prevent symptom 
and 1 of these (2.3%) had symptom recurrence. Therefore, 
the recurrence of symptom was more frequently noted in 
patients with medication than those without medication 
(p=0.014) (Fig. 4). Of 46 patients with low episodes of symp-
toms, six patients were on medication to prevent symptom re-
currence. Two these (33.3%) experienced symptom recur-
rence, whereas 40 patients did not take any medication to 
prevent symptom. Seven of the 40 patients (17.5%) had symp-
tom recurrence. Therefore, the recurrence of symptoms was 
more frequently observed in patients with medication than 
those without medication (p=0.01) (Fig. 4).
Clinical predictors of the recurrence of symptoms 
By multivariate logistic regression analysis, significant pre-
dictors of the recurrence of symptoms were symptom fre-
quency and medication (Table 3).
Discussion
Neurocardiogenic syncope is the most common cause of 
syncope. Symptom recurrence is unpredictable however and 
sometimes a long, symptom free period is observed. 
Several studies evaluated the rate of symptom recurrence 
in patients with neurocardiogenic syncope during the follow-
up period. However, a significant difference in the recurrence 
rate among the studies was observed. Ruiz et al.
6) reported 
that the recurrence rate was 8.9% in patients with neurocar-
diogenic syncope, who experienced more than one episode of 
syncope and did not take any medication to prevent symp-
tom. Brignole et al.
9) stated that the recurrence rate was 27% 
Fig. 2. Recurrence of symptoms in patients with high and low epi-
sodes of symptom during follow-up.
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Fig. 3. Comparison of recurrence rate between the high episode gr-
oup and low episode group. The recurrence of symptoms was sig-
nificantly less in the high episode group than in the low episode 
group (5.6% vs. 19.6%, p=0.001).
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Fig. 4. Comparison of recurrence rate based on drug treatment in patients with high episode (A) and low episode (B) of symptoms. The recurrence 
of symptoms was more frequently observed in patients with medication than in those without medication in both groups (p=0.01).
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Table 3. Predictors of recurrence of symptoms in multivariate lo-
gistic regression analysis
Predictor variables OR 95% confidence interval
Sex 0.398 0.098-1.614
Age 1.000 0.955-1.047
Frequency* 0.201 0.045-0.892
Underlying disease 0.782 0.130-4.713
Medication† 5.877 1.051-32.855
Physical injury 0.462 0.079-2.704
*p=0.035, †p=0.044. OR: odds ratio in multiple logistic regression438   Recurrence Rate in Neurocardiogenic Syncope
or 20% in 30 patients on placebo or atenolol, respectively. 
Sheldon et al.
7) reported that there was 28% of symptom re-
currence in 101 patients without medication during 3 year 
follow-up. Natale et al.
10) reported different recurrence rates 
according to treatment. The recurrence rate was 6% in pa-
tients who were treated on drugs guided by repeat HUT, 36% 
in patients with empirical drug treatment, and 67% in pa-
tients without drug treatment. Cox et al.
11) reported that the 
recurrence rate was 42% in patients who stopped drugs, wh-
ich was effective on repeat HUT. Ahn et al.
12) reported that the 
recurrence rate was 7.1% in patients who were treated on 
drugs guided by repeat HUT, 16.7% in patients with empiri-
cal drug treatment, and 22.4% in patients who stopped drug 
during follow-up. 
In our study, the recurrence rate was 12% in 100 patients 
during 38.4±3.6 months. Interestingly, we found that the re-
currence rate was lower in high episode group compared to 
the low episode group (5.6% vs. 19.6%) following HUT. In 
contrast to our report, Sheldon et al.
7) stated that symptom 
recurrence was related to the frequency of symptom episodes 
before HUT. Kouakam et al.
13) and Barón-Esquivias et al.
14) 
also reported similar results and proposed that the frequen-
cy of symptoms before HUT as a predictor of symptom re-
currence during follow-up. We also evaluated a predictor of 
symptom recurrence by multivariate logistic regression an-
alysis. Significant predictors of the recurrence of symptoms 
were symptom frequency and medication. The different re-
sults obtained by us may be related to differences in the in-
clusion criteria of patients, HUT protocol, and the definition 
of symptom recurrence.
In the past, many physicians prescribed many different 
types of medication including β-blocker, theophylline, sero-
tonin-reuptake inhibitor, α-blocker, and other drugs to pa-
tients with neurocardiogenic syncope or presyncope based 
on their symptom frequency. However, prospective randomiz-
ed trials did not show any beneficial effect of those drugs ex-
cept midodrine.
15-20)
In our study, we started medication to prevent symptoms 
if patients complained of frequent symptoms. β-blocker was 
used as an initial drug to prevent symptoms. If patients still ex-
perienced symptoms, β-blocker was stopped and other me-
dications such as theophylline, midodrine, fluoxetine were used 
as second drugs. If patients showed a positive response at the 
first phase of HUT, β-blocker was not used as the initial drug 
to prevent symptoms. Other drugs such as theophylline, mi-
dodrine, and fluoxetine were used as the initial drugs to pre-
vent symptoms. Interestingly, the recurrence of symptoms 
was more frequently noted in patients with medication than 
those without medication regardless of high and low episode 
groups. This finding in our study might be related to several 
factors such as frequent episodes of symptoms in treated gr-
oups and disappointing results of drug efficacy. Recent Euro-
pean Society of Cardiology guidelines emphasizes patient edu-
cation, avoidance of triggers, and prompt position change at the 
prodromal symptoms rather than prescribing medications.
21) 
Study limitation
This study was retrospective in design and seventy six of 
the total 176 consecutive patients were excluded from the an-
alysis because they did not participate in a telephone inter-
view during the follow-up period. The study population in-
cluded both patients with neurocardiogenic syncope and 
presyncope. We also used a different HUT protocol to confirm 
neurocardiogeic syncope or presyncope. Taken together, these 
factors might affect the results of our study. 
Conclusion
In our study, the frequency of previous symptoms at the 
diagnosis of neurocardiogenic syncope or presyncope did 
note predict the occurrence of symptoms during the follow-
up period. Therefore, it is inadvisable to continue drug treat-
ment based on the frequency of symptoms in patients with 
neurocardiogenic syncope or presyncope.
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